Zimmer Biomet Holdings, Inc. (ZBH) fair value analysis
S&P 500 · Updated 2026-10-19
ZBH price how computed
Forward Fair Value verdict
UndervaluedZBH is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $89.14
- Sector
- Healthcare
- 12-month range
- $79.58–$103.18
- Market cap
- $17B
- From 52-week high
- -13.6%
- Shares outstanding
- 191M
- Rank in Healthcare by discount to fair value
- #24 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Zimmer Biomet Holdings, Inc. is a global medical device company that designs, manufactures, and markets orthopedic implants, surgical products, and related technologies for joint replacement, trauma, spine, and other orthopedic procedures. The company operates in multiple countries across North America, Europe, Asia Pacific, and other international markets.
ZBH currently ranks #24 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $17B
- P/E (trailing)
- 11x
- Revenue (TTM)
- $8.51B
- Net margin
- 9.5%
- EPS (TTM)
- $8.48
- Gross margin
- 70.8%
- Debt / equity
- 0.59
- Revenue growth (3-yr avg)
- 8.0%
- Shares outstanding
- 191M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 56 · neutral
- 50-day average
- $95.28
- 200-day average
- $91.39
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $0.96 per share (4 payments)
- Yield on last price
- 1.08%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-09-30
- Last payment date
- 2026-10-30
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 7 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+3.0%)
2026-03 ▲ beat (+12.4%)
2025-12 ▲ beat (+0.8%)
2025-09 ▲ beat (+1.1%)
2025-06 ▲ beat (+4.5%)
2025-03 ▲ beat (+2.3%)
2024-12 ▲ beat (+0.9%)
2024-09 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 18 hold · 0 sell (27 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $107
- Target vs last price
- +20.0%
What our data shows for ZBH
- Our model validated 17 trailing price-to-earnings windows for ZBH, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $79.58–$103.18.
- The 14-day relative strength index sits at a neutral 56.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ZBH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ZBH news
TickrTrends' derived news-sentiment signal for ZBH is currently leaning positive, computed from recent coverage.
- Is It Too Late to Buy Zimmer Biomet Holdings Inc (ZBH) After 3.4% Rally? GF Value Says Undervalued (gurufocus.com, 2026-10-12)
TickrTrends take: Zimmer Biomet Holdings Inc operates in the Healthcare sector where valuation multiples can vary significantly based on product pipeline strength and procedural volume trends. TickrTrends currently derives an undervalued verdict for ZBH, which aligns with the GF Value assessment referenced in the headline, suggesting the stock may offer value at present price levels. Investors focused on valuation metrics should monitor whether the company can sustain margin expansion and procedure growth rates, as these factors directly influence whether the current pricing reflects an attractive entry point or represents a temporary dip in a higher-priced trend. - A Look at Zimmer Biomet Holdings Inc (ZBH) After 3.7% Gain -- GF Value $125.41 vs Price $91.57 (gurufocus.com, 2026-10-05)
TickrTrends take: Zimmer Biomet Holdings is trading at a significant discount to its GF Value estimate, with the stock price approximately 27% below the valuation benchmark at current levels. This gap aligns with TickrTrends' undervalued assessment for the orthopedic and surgical device manufacturer in the Healthcare sector. Investors focused on valuation metrics should monitor whether the stock continues to approach its estimated fair value or if the discount persists amid broader market conditions affecting medical device companies. - Citi Initiates 90-Day Watch on Zimmer Biomet (ZBH) Ahead of Q3 Earnings (gurufocus.com, 2026-10-05)
TickrTrends take: Zimmer Biomet operates in the Healthcare sector where Citi's decision to initiate a 90-day watch period suggests upcoming catalysts that could influence the company's valuation trajectory. TickrTrends currently rates ZBH as undervalued, which means investors following the analyst's watch period may be positioned to observe how Q3 earnings results either validate or challenge that assessment. The combination of elevated analyst scrutiny and an undervalued designation indicates this period could present significant movements in how the market prices the company's fundamentals.
What people are saying
Follow the ZBH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — # ZBH Weekly Summary TickrTrends' derived indicators for ZBH showed a shift this week as the DCF cross-check band moved from an undervalued assessment to a fairly valued assessment. Despite this change in the DCF metric, the current overall valuation verdict remains undervalued. The movement suggests evolving analyst perspectives on the healthcare company's intrinsic value relative to its current market price.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for ZBH show movement toward undervaluation this week. The DCF cross-check band shifted from fairly valued to undervalued, aligning with the current valuation verdict that ZBH is undervalued. This change suggests the Healthcare sector company's intrinsic value estimate has increased relative to its current market price.
- 2026-09-21 — ZBH's momentum indicator declined this week, dropping from a B rating to none, suggesting a weakening of upward price movement. Despite this deterioration in momentum, the stock maintains an undervalued status according to TickrTrends' valuation assessment.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ZBH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ZBH is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ZBH's TickrTrends verdict?
ZBH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ZBH compare to other Healthcare stocks?
ZBH ranks #24 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ZBH overbought or oversold?
ZBH's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ZBH pay a dividend?
Yes. ZBH paid $0.96 per share over the last twelve months (4 payments), a 1.08% yield on TickrTrends' last price. The last ex-dividend date was 2026-09-30.
When does ZBH report earnings next?
ZBH's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does ZBH usually beat earnings estimates?
Over its last 8 reported quarters ZBH beat the consensus estimate 7 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ZBH?
Of 27 analysts covering ZBH, 9 rate it a buy, 18 a hold and 0 a sell - hold-leaning, with a consensus price target of $107 (+20.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ZBH vs ABT · ZBH vs AMPH · ZBH vs CI · ZBH vs DVA · ZBH vs GEHC